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Abstract
Background: Bladder pain syndrome (BPS) pathology is poorly understood. Treatment
strategies are empirical, with limited efficacy, and affected patients have diminished
quality of life.
Objective: We examined the hypothesis that inﬂammatory mediators within the bladder
contribute to BPS pathology.
Design, setting, and participants: Fifteen women with BPS and 15 women with stress
urinary incontinence without bladder pain were recruited from Cork University Maternity
Hospital from October 2011 to October 2012. During cystoscopy, 5-mm bladder biopsies
were taken and processed for gene expression analysis. The effect of the identiﬁed genes
was tested in laboratory animals.
Outcomemeasures and statistical analysis: We studied the expression of 96 inﬂammation-
related genes in diseased and healthy bladders.Wemeasured the correlation between genes
and patient clinical proﬁles using the Pearson correlation coefﬁcient.
Results and limitations: Analysis revealed 15 differentially expressed genes, conﬁrmed in a
replication study. FGF7 and CCL21 correlated signiﬁcantly with clinical outcomes. Intrave-
sical CCL21 instillation in rats caused increased bladder excitability and increased c-fos
activity in spinal cord neurons. CCL21 atypical receptor knockout mice showed signiﬁcantly
more c-fos upon bladder stimulation with CCL21 than wild-type littermates. There was no
change in FGF7-treated animals. The variability in patient samples presented as the main
limitation. We used principal component analysis to identify similarities within the patient
group.
Conclusions: Our study identiﬁed two biologically relevant inﬂammatory mediators in
BPS and demonstrated an increase in nociceptive signalling with CCL21. Manipulation of
this ligand is a potential new therapeutic strategy for BPS.
Patient summary: We compared gene expression in bladder biopsies of patients with
bladder pain syndrome (BPS) and controls without pain and identiﬁed two genes that
were increased in BPS patients and correlated with clinical proﬁles. We tested the effect
of these genes in laboratory animals, conﬁrming their role in bladder pain. Manipulating
these genes in BPS is a potential treatment strategy.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
* Corresponding author. Neurorestoration Group, Wolfson CARD, King’s College London, Hodgkin
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1. Introduction
Bladder pain syndrome (BPS) is pain related to the urinary
bladder accompanied by frequency, urgency, or nocturia,
with the exclusion of any other diseases of the lower urinary
tract [1,2]. Although the disease affects both sexes, women
are more commonly affected than men by 5:1 [3]. Some
patients display a mild form of the disease, with treatment
generally orchestrated in the outpatient setting; in other
cases, the disease is debilitating and requires prolonged
hospitalisation and, often, repeated surgical intervention.
The aetiology of BPS is unknown. Multiple theories exist,
including epithelial disruption and mast cell and vascular
abnormalities [4,5]. The contributions of peripheral neuronal
mechanisms remain unclear. We explore the hypothesis that
many patients have a peripheral inflammatory disorder and
that the expression of inflammatorymediators in the bladder
wall activates and sensitises the bladder sensory afferents,
driving BPS symptoms. Because there are currently no
disease-modifying treatments for BPS, we postulated that
the identification of novel inflammatory mediators associat-
ed with the disease might be manipulated to alter the
disease’s course.
We used quantitative gene expression analysis of
96 inflammatory mediators to measure gene expression
levels in BPS and control samples.We then tested the activity
of the identified mediators in an animal model of BPS using
the enzymes chondroitinase and heparanase to digest the
proteoglycan barrier [6,7].
2. Materials and methods
We performed a prospective observational study of 15 women with BPS
and 15 age-matched female controls between October 2011 and October
2012 at Cork University Maternity Hospital. BPS participants had bladder
pain for at least 3 mo, with urodynamic and cystoscopic evidence of
disease. Controls were patients undergoing tension-free vaginal tape
surgery. Patients who had systemic disease such as malignancy,
coagulopathies, or other forms of cystitis (eg, infective, chemical, or
radiation cystitis) were excluded.
Participants completed the O’Leary-Sant Interstitial Cystitis Symp-
tom and Problem Index (ICS/PI) questionnaire. While under general
anaesthesia, a rigid cystoscopy ( [18_TD$DIFF]308 lens) was performed, and three
5-mm biopsies were taken from above the bladder trigone by cold-cup
biopsy technique from each participant [7]. Biopsies were also taken
from healthy-looking bladder away from lesion sites. RNAwas extracted
from the tissue using a combination of phenol extraction and column
puriﬁcation. RNA integrity was determined using an Agilent RNA
6000 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).
We performed reverse transcription reactions using a complemen-
tary DNA reverse transcription kit (Invitrogen; Thermo Fisher Scientiﬁc,
Waltham, MA, USA). Custom-made TaqMan microﬂuidic cards (Applied
Biosystems; Thermo Fisher Scientiﬁc, Waltham, MA, USA) were used to
measure expression levels of 96 inﬂammatory mediators in disease
versus control tissue calculated using the DCT (cycle time) method [8]
and normalised against the geometricmean of three housekeeping genes
using the ReadqPCR and NormqPCR packages [9].
2.1. Patient clustering
We used principal component analysis with eigenvalue decomposition to
visualise biologic variability within the patient group [10]. We identiﬁed
patient clusters based on their gene expression levels and used the ﬁrst
two components for repeat gene expression analysis. Pearson correlation
coefﬁcient was used to visualise the hierarchical clustering of each group
of patients for signiﬁcantly dysregulated genes.
2.2. Replication study
Conﬁrmatory gene expression analysis was replicated in an independent
cohort of 23 patientswith bladder pain and 15 controlswithout pain. BPS
was diagnosed based on history of bladder pain, and control participants
were patients who had lower urinary tract disorders such as stress
urinary incontinence or overactive bladder without pain. Biopsies were
taken under general anaesthesia from the bladder dome away from
lesion sites using the cold-cup biopsy technique.
2.3. Statistical analysis
Data analysis was performed using the DCT method [8]. We applied the
Benjamini-Hochberg false discovery rate (FDR) algorithm (5%) to the
data. We used a volcano plot to illustrate variation within the data, thus
visually highlighting differentially regulated genes (t test p value = 0.01;
twofold difference). Spearman rank correlation was used to determine
the correlation of gene expression levels against BPS clinical phenotypes
derived from the ICS/PI questionnaire.
2.4. Animal experiments
All experiments were conducted using adult female Wistar rats
(approximate weight: 200–250 g, Harlan, UK) in accordance with the
UK Home Ofﬁce Regulations. All rats were housed in the licensed
biological services unit of King’s College London with a 12-h day/night
cycle. Food and water were available at all times. Each animal was
randomly assigned to treatment protocols, and assessors were blinded to
the treatments the rats received.
2.5. Cystometry
Fifteen animals were anaesthetised with 1 mg/kg urethane; 20-gauge
catheters were inserted transurethrally and attached to a syringe pump
and pressure transducer. Bladders were distended with 0.9% saline, with
50 ml/min and baseline cystometric analysis recorded. Ten animals had
200 ml of 0.25 IU chondroitinase ABC and heparanase III (Sigma-Aldrich,
St. Louis, MO, USA) bladder instillation. Five control animals had 200 ml
phosphate-buffered saline (PBS) instilled, and solutions were allowed to
remain in situ for 2 h. Then, ﬁve animals each had 10 ml of 250 ng/ml of
either CCL21 or FGF7 instilled for 2 h. Cystometric analysis was repeated,
and total contraction time was measured.
2.6. Behavioural assessment
Pelvic pain response was assessed using calibrated Von Frey monoﬁla-
ments. Von Frey withdrawal is typically performed on the hind paw of
laboratory animals.Weperformedmechanicalwithdrawal assessment on
the suprapubic region, which is reported as a valid method for the
assessment of referred hyperalgesia and mechanical allodynia in animal
models of bladder hypersensitivity [11]. Tactile sensitivity of the
suprapubic regionwas assessedusing theChaplanmethod [12]. A positive
behavioural response was recorded as licking or scratching of the
stimulated area, sharp withdrawal, or jumping. Rats were anaesthetised
with isoﬂurane and transurethrally catheterised; 10 rat bladders were
permeabilised with 200 ml of 0.25 IU chondroitinase ABC and heparanase
III. Experimental rats received 10 ml of 250 ng/ml CCL21 or FGF7
postdigestion (ﬁve per group), while ﬁve controls received PBS. Von Frey
assessment was repeated, and 50% threshold values were calculated.
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2.7. Spinal c-fos expression
Fifteen animals were anaesthetised with urethane, transurethrally
catheterised, and treated with 200 ml of 0.25 IU chondroitinase ABC and
heparanase III. Then, ﬁve animals each had 10 ml of 250 ng/ml of either
CCL21 or FGF7 instilled. Five control animals were catheterised without
bladder instillation. After 2 h, all animals were sacriﬁced and transcar-
dially perfusedwith 4%paraformaldehyde (VWR, Lutterworth, UK). Spinal
cord sections L6–S1were collected, cryoprotected, embedded, and frozen.
Serial (20 mm) sections were cut and stained for c-fos. In brief, sections
were incubated for 48 h in a 1:1000 dilution of rabbit c-fos antibody
(Cell Signalling Technology, Danvers, MA, USA), with a 1:500 dilution of
mouse monoclonal anti-Neu N antibody (Merck Millipore, Darmstadt,
Germany) in 10% normal donkey serum. Sections were washed with PBS,
then incubated in secondary antibodies of donkey antimouse Alexa Fluor
488 (Thermo Fisher Scientiﬁc) and donkey antirabbit Alexa Fluor 546
(1:500; Thermo Fisher Scientiﬁc) for 2 h. Sections were washed and
mounted with VECTASHIELD Antifade Mounting Medium with DAPI
(Vector Laboratories, Burlingame, CA, USA). Images were taken using a
ZEISS LSM 710 confocal microscope (Oberkochen, Germany). Cells
exhibiting c-fos immunoreactivity were counted in the afferent regions
of the spinal cord.
2.8. CCL21 atypical receptor knockouts
We received 17 C57/BL6/J mice from The Beatson Institute for Cancer
Research, Glasgow: 9 ACKR4 / receptor knockout and 8 wild-type
littermates [13]. The mice were anaesthetised with urethane, cathe-
terised, and bladder permeabilised using 150 ml of 0.25 IU chondroi-
tinase ABC and heparanase III. Then, 10 ml of 250 ng/ml CCL21 was
instilled for 2 h, following which all animals were sacriﬁced, perfused,
ﬁxed, and spinal c-fos staining performed.
3. Results
BPS participants had urodynamic and cystoscopic evidence
of disease. Control participants had no urologic disease or
pain symptoms. All participants were free from urinary tract
infections. See supplementary material for further pheno-
typic details.
Gene expression analysis of 96 inflammation-
related genes revealed 15 differentially regulated genes
(fold change>2; p < 0.05), highlighting a clear inflammatory
process in theBPSpathology (Fig. 1A).Thevolcanoplot shows
the five most dysregulated genes (CCL21, IL12A, CXCL1, TNF,
and FGF7 [shown in red]), which were all significantly
dysregulated after correcting p values using the FDRmethod
of Benjamini-Hochberg, with a 5% FDR.
3.1. Gene correlation with clinical phenotypes
Spearman rank correlation was used to compute correlation
between the dysregulated genes and patient clinical
phenotypes; it revealed that CCL21 and FGF7were positively
correlated with patient clinical phenotypes for ICS/PI
symptom and problem indices, respectively (Fig. 2). In the
case of CCL21, the correlation was statistically significant.
3.2. Principal component analysis
We applied principal component analysis to the entire gene
expression data set (15 BPS and 15 controls) to visualise
variability in the data. Figure 3A shows the first two
dimensions of this analysis, fromwhichwe identify a cluster
of seven BPS and seven controls that were tightly grouped.
Further analysis of these principal component analysis–
selected cohorts by hierarchical clustering revealed, as
expected, a striking reproducibility among patients for all
differentially regulated genes (Fig. 3B). A DCT analysis of this
refined group revealed 35 significantly dysregulated inflam-
matory genes, including CCL21 and FGF7.
3.3. Replication study
We performed a transcriptional analysis on an independent
cohort of patients. In this cohort, hierarchical clustering
revealed large biologic variability (Fig. 4A), but principal
component analysis revealed a cluster of 5 pain and
6 controls, DCT analysis of which showed significant
dysregulation of 15 inflammatory genes, including again
CCL21 and FGF7 (Fig. 4B). This gene dysregulation pattern
for both the original cohort and the principal component
analysis–selected cluster correlated with that of the
primary study (Fig. 4C).[(Fig._1)TD$FIG]
Fig. 1 – Gene expression analysis of all patients. (A) Gene expression levels in bladder biopsies of bladder pain syndrome (BPS) patients versus controls.
Each point represents the mean fold change (FC) for each gene transcript, displayed as the log2 of the FC. Each point is ranked in order of FC, commencing
with the genes with the lowest FC to those that are most upregulated (compared to controls). The green box denotes genes with FC W2. FC ranking
revealed that a considerable number of genes were upregulated in the data set. (B) Volcano plot visualising the genes separated according to their
expression FC (x-axis) and significance (y-axis: log10 p value) in BPS and controls. Genes highlighted in red had log2 FC >2 and log10 p values <0.01 in our
data set.
FC = fold change.
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3.4. Preclinical studies
3.4.1. CCL21 increases bladder contractions and pain-related
behaviour
To assess the effect of CCL21 and FGF7 in laboratory animals,
we permeabilised the bladders of female Wistar rats using
chondroitinase ABC and heparanase III to digest proteogly-
cans of the mucosal barrier, then applied the ligands
intravesically. Cystometric analysis revealed an increase in
bladder contraction number following enzymatic deglyco-
sylation, which was sustained but not additive after CCL21
treatment (p = 0.0067). There was no change from baseline
following FGF7 treatment (p = 0.320) (Fig. 5A and 5B).
In addition, behavioural pain assessment showed a signifi-
cant decrease in the mechanical withdrawal threshold
following deglycosylation, with withdrawal thresholds
[(Fig._3)TD$FIG]
Fig. 3 – Principal component analysis and hierarchical clustering. (A) Principal component analysis of all patients analysed, evaluated based on their
gene expression profiles. The first two principal components, consisting of two clusters of seven bladder pain syndrome (BPS) patients and seven
controls, are circled in red. (B) Hierarchical clustering of differentially regulated genes of the seven BPS and seven control patients identified with the
principal component analysis. Green denotes upregulated genes, whereas red denotes downregulated genes.
BPS = bladder pain syndrome.
[(Fig._2)TD$FIG]
Fig. 2 – Correlation of gene relative expression with patient clinical phenotypes. Spearman rank correlation coefficient of the seven bladder pain
syndrome patients, selected using principal component analysis, with the clinical phenotypes. There was a positive correlation between transcript
expression for CCL21 and FGF7 and the O’Leary-Sant Interstitial Cystitis Symptom and Problem Index questionnaire scores (CCL21 r = 0.93, p = 0.0067;
FGF7: r = 0.61, p = 0.17).
BPS = bladder pain syndrome; ICS/PI = O’Leary-Sant Interstitial Cystitis Symptom and Problem Index.
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further decreasing following CCL21 treatment. There was no
difference inwithdrawal threshold in the FGF7 or control rats
(Fig. 5C).
3.4.2. CCL21 leads to upregulation of spinal c-fos
The effect of the ligands on spinal neurone activation was
assessed by immunolocalisation of the immediate-early
gene, c-fos, in anaesthetised rats following bladder permea-
bilisation. Analysis revealed a significant increase in the
c-fos–positive cell number following urothelial permeabi-
lisation compared to the saline-treated controls (p = 0.036).
There was a further significant increase following CCL21
treatment (p = 0.042). There was no significant difference
between the animals after permeabilisation alone com-
pared to those after FGF7 treatment (p = 0.27) (Fig. 6B).
To assess the role of the CCL21 atypical chemokine
receptor 4 (ACKR4) on bladder pain, we performed immu-
nolocalisation of c-fos on ACKR4 knockout mice and wild-
type littermates. Assessment revealed a significant increase
in the number of c-fos–positive cells in the ACKR4 knockout
mice compared to the wild-type controls (Fig. 6A and 6C).
4. Discussion
Our study shows upregulation of specific genes encoding
inflammatorymediators in bladder biopsies of BPS patients.
We also showed a significant correlation between mRNA
levels of the genes FGF7 and CCL21 with patient clinical
profiles and disease severity scores. In addition, we
highlighted the role of CCL21 as a pain mediator in an
animal model of BPS.
In the past 20 yr, various animal models of cystitis have
been created [14]. These models rely on inflammation of
the bladder urothelium and so replicate only part of the
pathology of the human disease. We have disrupted the
bladder barrier by specific deglycosylation of urothelial
proteoglycan molecules, thus replicating the disease,
because 80% of BPS patient bladder biopsies show features
of a defective barrier [15].
The key problem with human analysis is biologic
variability, especially with complex diseases like BPS. In
our study, principal component analysis revealed clear
biologic variability in the participants analysed, but it also
identified a cluster of patients who had distinct transcrip-
tional profiles, suggesting that although a substantial
number of patients share common inflammatory pathology,
this does not apply to all patients. We therefore used this
method to examine the biologic variability of the replication
study, identifying a cluster with a strongly described
inflammatory phenotype. The replication study was not
designed to be a formal biologic replicate. The recruitment
criteria for that study were slightly different and less
[(Fig._4)TD$FIG]
Fig. 4 – Replication study and correlation with primary study. (A) Hierarchical clustering of all participants, showing large biologic variability.
(B) Hierarchical clustering of the principal component analysis–selected first two components, showing the correlation between patients and genes.
(C) Each point represents the fold change (FC) difference for each gene from the discovery and replication study. The left panel corresponds to the
correlation of the FCs for all patients included in both analyses (R2 = 0.23, p = 0.03). The second panel represents the seven bladder pain syndrome
versus seven controls from the initial study, correlated with the five pain patients and six controls from the replication study (R2 = 0.32; p = 0.01).
Significance was calculated using Pearson R with a 2-tailed t test and a 95% confidence interval.
FC = fold change.
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exhaustive than the original one, but we took the
opportunity to replicate the analysis in a similar cohort
of patients with bladder pain.
The modest number of participants represents the main
limitation of our study. This is a consequence of the difficulty
of recruiting BPS patients resulting from the inherent
diagnostic complexity of this syndrome. This sample size
is, however, similar to previous studies in publication
evaluating gene expression profiles of bladder biopsies from
BPS patients as well as a quantitative analysis of gene
expression, which, although small, were able to detect
differences [16–19].
There is great heterogeneity of findings in the field of
molecularcharacterisationofBPS.Results varybecauseof the
complexity of the disease, the difficulty of diagnosis, the and
phenotypic variability inBPS patients.Wehave confirmed an
inflammatory component to the disease process. Several
candidate genes that were found upregulated in our study
have been reported as significant in BPS, including NOS, IL6,
IL8, IL10, IL17A, NGF, and TNFA [16,20,21]. Of these, we
identified two genes that correlated to patient phenotypes:
FGF7 and CCL21. FGF7, also known as keratinocyte growth
factor, expression is found to be upregulated in chronically
injured tissue [22]. FGF7 expression is associated with
healing and wound repair, supporting the integrity of the
gastrointestinal tract mucosal barrier in chemotherapy
patients who have oral mucositis [23,24]. It is possible that
upregulation of FGF7 has a similar action in BPS patient
bladders, strengthening urothelial barrier integrity. Our
results corroborate these findings; FGF7 treatment following
urothelial permeabilisation reduced bladder excitation on
cystometry and behaviour analysis. In addition, FGF7
treatment did not lead to an increase in c-fos–positive cell
numbers, suggesting that FGF7may be involved in repair of
the damaged urothelium.
CCL21, also knownas secondary lymphoid tissue chemokine,
is a potent inflammatory chemokine that regulates dendritic
cell migration and has been implicated in various chronic
inflammatory, fibrotic, and pain conditions, including
rheumatoid arthritis, neuropathic pain, idiopathic pulmo-
nary fibrosis, chronic hepatitis C, and primary biliary
cirrhosis [25–28]. In the central nervous system, CCL21
expression is increased in damaged neurons, leading to
increased microglial P2X4 expression [26]. It is possible
that CCL21 may be involved in similar inflammatory cell
activation in the periphery in response to injury. We have
[(Fig._5)TD$FIG]
Fig. 5 – Cystometry and behaviour assessment. (A) Representative cystometric recordings of bladders, showing contraction frequency following baseline
assessment, enzymatic proteoglycan deglycosylation, FGF7 treatment, and CCL21 treatment in permeabilised bladders. (B) Quantification of the
cystometric number of bladder contractions. Displayed is the mean total number of contractions in a 20-min interval W1 standard error of the mean
(SEM; five rats per group). Statistical significance calculated using one-way analysis of variance (ANOVA) with Bonferroni post-test correction. (C)
Behavioural assessment. Each point represents the mean mechanical withdrawal threshold as a percentage of baseline W1 SEM (five rats per group).
Statistical significance was calculated using two-way ANOVA with Bonferroni correction. The CCL21 treatment withdrawal threshold is significantly
lower than the control group and animals’ postenzymatic deglycosylation alone.
BPS = bladder pain syndrome; Ch’ase = chondroitinase; H’ase = heparanase; ns = not significant; Tx = treatment.
[3_TD$DIFF](B) * p < 0.05; ** p < 0.01. (C) * Significance difference in CCL21[1_TD$DIFF] from baseline [4_TD$DIFF]: [5_TD$DIFF]*** p < [6_TD$DIFF]0.001; [7_TD$DIFF]** p < 0.01; # significance[8_TD$DIFF] difference in treatment from
baseline[4_TD$DIFF]: [9_TD$DIFF]## p < [10_TD$DIFF] .01.
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shown that CCL21 activity leads to an increase in bladder
excitability and pain. The atypical CCL21 receptor ACKR4,
found in the epithelial cells of the heart, thymus, skin, and
urinary bladder, is a high-affinity receptor for CCL21 [29]. By
internalising its ligands, this receptor diminishes the
available circulating CCL21 levels, suppressing disease
severity [13]. In our study, the increased number of spinal
cells positive for c-fos in ACKR4/ suggests an increase in
circulating CCL21 and a consequent increased disease
severity. Thus, our study suggests that blockade of CCL21
in the bladder may have similar disease-modifying effects in
BPS patients.
5. Conclusions
We have used medium-throughput quantitative polymer-
ase chain reaction analysis to examine genes’ differences in
BPS and control biopsies and correlated gene expression to
disease phenotype. In addition, we highlighted the role of
CCL21 and FGF7 in BPS pain in rats and demonstrated an
increase in pain processing in mouse knockouts for the
CCL21 atypical receptor. Our results support the potential
for the molecular evaluation and manipulation of these
inflammatory mediators in the bladder as a possible new
treatment strategy for BPS.
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